Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences

Author： Baetta Roberta   Corsini Alberto  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.11, 2011-07, pp. : 1441-1467

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

By Ahrén Bo  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 4, 2008-12 ,pp. : 593-607

Informa Healthcare

Access to resources Recommend Favorite

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

By Scheen Andre  

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 545-557

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of cathepsin C (dipeptidyl peptidase I)

By Laine Dramane I   Busch-Petersen Jakob  

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 4, 2010-04 ,pp. : 497-506

Informa Healthcare

Access to resources Recommend Favorite

Recent patents of dipeptidyl peptidase IV inhibitors

By Mendieta Laura   Tarrago Teresa   Giralt Ernest  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1693-1741

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F   Holst Jens J  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite